Semaglutide is a synthetic GLP-1 receptor agonist peptide, supplied by Certiva as a lyophilized reference material for laboratory research use only
This program supports members at every stage of their journey whether theyre navigating menopause, using GLP-1 weight-loss medications, or simply looking to build sustainable movement into a healthier lifestyle
Ozempic is approved by the FDA for adults with type 2 diabetes to lower blood sugar, along with diet and exercise, reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes who also have heart disease, and lower the risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes who also have chronic kidney disease
Retatrutide adds a third receptor (glucagon), and early trial data suggests even greater weight loss potential, though it is not yet FDA-approved
Heres a closer look at how semaglutide works for weight loss and its mechanism of action: GLP-1 Receptor Agonist Semaglutide acts as a GLP-1 receptor agonist, mimicking the effects of a natural hormone called glucagon-like peptide-1 (GLP-1)
Government agencies like Australias Therapeutic Goods Administration indicate that supply will remain limited for the remainder of 2025
